Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic liver condition worldwide. Current liver enzyme-based screening methods have limitations that may missed diagnoses and treatment delays. Regarding Chen et al, the risk of developing MAFLD remains elevated even when alanine aminotransferase levels fall within the normal range. Therefore, there is an urgent need for advanced diagnostic techniques and updated algorithms to enhance the accuracy of MAFLD diagnosis and enable early intervention. This paper proposes two potential screening methods for identifying individuals who may be at risk of developing MAFLD: Lowering these thresholds and promoting the use of noninvasive liver fibrosis scores.
Original language | English |
---|---|
Pages (from-to) | 2839-2842 |
Number of pages | 4 |
Journal | World Journal of Gastroenterology |
Volume | 30 |
Issue number | 22 |
DOIs | |
State | Published - 2024 |
Externally published | Yes |
Keywords
- Alanine aminotransferase
- Liver enzymes
- Metabolic dysfunction-associated fatty liver disease
- Non-alcoholic fatty liver disease
- Noninvasive liver fibrosis scores
- Screening